American Academy of Neurology (AAN) 2025 Annual Meeting

Treatment with AXS-05 significantly delayed the time to relapse of agitation in patients with Alzheimer’s disease (AD) compared with placebo, according to the phase III ACCORD-2 trial presented at AAN 2025.

An investigational neuromodulation device that delivers a controlled flow of dry, room-temperature air through the nasal passage helps relieve migraine pain, as shown in a study.

The use of fremanezumab is safe and effective for the prevention of episodic migraine (EM) in children and adolescents as young as 6 years old, according to a study presented at AAN 2025.

Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.

Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.

Data from the phase IV DUET* study presented at AAN 2025 reinforce the potential of low-sodium oxybate (LXB) for the treatment of narcolepsy or idiopathic hypersomnia (IH).